Advanced Deep Plane Facelift Center of Excellence Highlights Sophisticated Bucket Handle Platysmaplasty Technique at Kalos Facial Plastic Surgery

Double board-certified facial plastic surgeon Dr. Benjamin C. Stong advances deep plane facelift surgery through comprehensive platysma release and resuspension designed to enhance neck contour and ...
Monthly Prescribing Reference

Botox Cosmetic Approved for Moderate to Severe Platysma Bands

In both phase 3 trials, onabotulinumtoxinA significantly improved platysma band severity at maximum contraction compared with placebo. The Food and Drug Administration (FDA) has approved Botox ® ...
Yahoo

I Tried the “Nefertiti Lift” to Define My Jawline

Add Yahoo as a preferred source to see more of our stories on Google. Courtesy of Dr. Jennifer Levine Queen Nefertiti ruled Egypt during the 14th century BC. Some 3,500 years later, the world is still ...
Healio

Positive topline results show Botox Cosmetic may improve aesthetics of platysma prominence

Please provide your email address to receive an email when new articles are posted on . Results showed statistically significant improvement in platysma prominence after treatment with Botox Cosmetic ...
Healio

FDA approves Botox Cosmetic for platysma bands

Please provide your email address to receive an email when new articles are posted on . Botox Cosmetic temporarily decreases platysma muscle activity. It is the first product with four aesthetic ...
Seeking Alpha

BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)

IRVINE, Calif., Oct. 18, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie (ABBV) company, announced the U.S. FDA approval of BOTOX ® Cosmetic for temporary improvement in the appearance of ...
Seeking Alpha

Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence

–All primary and secondary endpoints were met for second Phase 3 study (M21-310) and results were consistent with findings from first Phase 3 study (M21-309). –Results support onabotulinumtoxinA as a ...